{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-254581","form_type":"8-K","ticker":"AVLN","cik":"0001540171","company_name":"Avalyn Pharma Inc.","filed_at":"2026-06-03T11:25:05+00:00","discovered_at":"2026-06-03T11:30:00.276090+00:00","generated_at":"2026-06-03T11:31:03.388198+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Avalyn Pharma reports Q1 net loss of $26.9M; MIST Phase 2b enrollment on track","bullets":["Net loss of $26.9M in Q1 2026 vs $17.5M in Q1 2025; R&D expense rose to $22.9M.","Cash, equivalents and marketable securities of $123.1M as of March 31, 2026; excludes $316.1M net IPO proceeds raised in May 2026.","MIST Phase 2b trial of AP01 in PPF enrollment on schedule to complete mid-2026; topline data expected H2 2027.","AURA Phase 2 trial of AP02 in IPF underway; first patient dosed March 2026; topline data expected late 2027.","Appointed Adam Golden as General Counsel and Head of BD, and Frank Salisbury as SVP Commercial."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-254581","json":"https://secwatch.observer/filing/0001193125-26-254581.json","markdown":"https://secwatch.observer/filing/0001193125-26-254581.md","text":"https://secwatch.observer/filing/0001193125-26-254581.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1540171/000119312526254581/0001193125-26-254581-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1540171/000119312526254581/ck0001540171-20260603.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T11:31:03.388198+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8a3a220ac5827c625e271ed7420bedfec07c9552","claim":"Avalyn Pharma Inc. reported the first quarter ended March 31, 2026 results: net income Net loss was $26.9 million.","evidence_excerpt":"Avalyn Pharma Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1540171/000119312526254581/0001193125-26-254581-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Net income","value":"Net loss was $26.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}